Development of assays for measurement of blocking and modulating autoacetylcholine receptor antibodies using rhabdomyosarcoma cells

Update Item Information
Title Development of assays for measurement of blocking and modulating autoacetylcholine receptor antibodies using rhabdomyosarcoma cells
Publication Type thesis
School or College School of Medicine
Department Pathology
Author Astill, Mark E.
Date 1993-12
Description Autoimmune pathologies result from an immune response against autologous antigens. In myasthenia gravis autoantibodies are directed toward acetylcholine receptors (AChR) causing a disruption in neuromuscular transmission. Although testing is available for measurement of a heterogeneous binding autoantibody population, recent evidence suggests that specific modulating and blocking antibodies correlate more closely with disease status. General AChR binding antibodies are measured with 125I-bungarotoxin (125I-aButx) and solubilized human AChR in an immunoprecipitation RIA. Specific blocking and modulating antibodies are measured with a sequential RIA using rhabdomyosarcoma (RD) cells. The anchorage dependent cells are grown in vitro, enzymatically released and used as a "free" suspension. Expression of receptor was measured as was equivalence of RD-AChR to other sources. Performance of the specific systems was evaluated. Over 100 samples submitted for binding were also tested for blocking and modulating antibody. HPLC of endocytosed 125I1Vutx and AChR binding ability was measured. Binding antibody was also measured in autoimmune thyroid receptor antibody (TRAB) sample. Approximately 2.2 x 10(6) RD cells were used per test at a ratio of 10 mL patient sera/million cells. Maximum radiolabel binding to cells was observed in approximately 4 hours with a Kd of 5.3 x 10-(10)M. Within-assay imprecision was less than 14% and 18% for blocking and modulating assays respectively. Of the 107 samples tested, 57 were negative for all three antibodies and 31 testes positive. Using the binding assay only, 32% of the population were classified positive. When specific antibody tests were included 46% were positive. Endocytosed radiolabel lost 80% of receptor binding capacity and may be altered in size TRAB samples appeared to have higher AChR-binding than controls. The AChR binding assays is not capable of measuring all relevant antoantibodies. The RD assays proved added capability. However, there remain autoantibodies not measured by any of these assays. Future studies with clinically defined samples are necessary.
Type Text
Publisher University of Utah
Subject Autoantibodies; Acetylcholine - Receptors; Autoimmune diseases; Myasthenia gravis
Subject MESH Autoantibodies; Receptors, Cholinergic; Autoimmune Diseases; Myasthenia Gravis
Dissertation Institution University of Utah
Dissertation Name MS
Language eng
Relation is Version of Digital reproduction of "Development of assays for measurement of blocking and modulating autoacetylcholine receptor antibodies using rhabdomyosarcoma cells". Spencer S. Eccles Health Sciences Library.
Rights Management © Mark E. Astill.
Format application/pdf
Format Medium application/pdf
Format Extent 1,447,020 bytes
Identifier undthes,4305
Source Original: University of Utah Spencer S. Eccles Health Sciences Library (no longer available).
Master File Extent 1,447,099 bytes
ARK ark:/87278/s6d79d8m
Setname ir_etd
ID 191610
Reference URL https://collections.lib.utah.edu/ark:/87278/s6d79d8m
Back to Search Results